245 related articles for article (PubMed ID: 25647343)
1. A shift toward T helper 2 responses and an increase in modulators of innate immunity in depressed patients treated with escitalopram.
Ho PS; Yeh YW; Huang SY; Liang CS
Psychoneuroendocrinology; 2015 Mar; 53():246-55. PubMed ID: 25647343
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and tolerability of escitalopram versus citalopram in major depressive disorder: a 6-week, multicenter, prospective, randomized, double-blind, active-controlled study in adult outpatients.
Yevtushenko VY; Belous AI; Yevtushenko YG; Gusinin SE; Buzik OJ; Agibalova TV
Clin Ther; 2007 Nov; 29(11):2319-32. PubMed ID: 18158074
[TBL] [Abstract][Full Text] [Related]
3. The plasma levels of various cytokines are increased during ongoing depression and are reduced to normal levels after recovery.
Dahl J; Ormstad H; Aass HC; Malt UF; Bendz LT; Sandvik L; Brundin L; Andreassen OA
Psychoneuroendocrinology; 2014 Jul; 45():77-86. PubMed ID: 24845179
[TBL] [Abstract][Full Text] [Related]
4. Effects of escitalopram/quetiapine combination therapy versus escitalopram monotherapy on hypothalamic-pituitary-adrenal-axis activity in relation to antidepressant effectiveness.
Nothdurfter C; Schmotz C; Sarubin N; Baghai TC; Laenger A; Lieb M; Bondy B; Rupprecht R; Schüle C
J Psychiatr Res; 2014 May; 52():15-20. PubMed ID: 24513501
[TBL] [Abstract][Full Text] [Related]
5. [Clinical efficacy and achievement of a complete remission in depression: increasing interest in treatment with escitalopram].
Favré P
Encephale; 2012 Feb; 38(1):86-96. PubMed ID: 22381728
[TBL] [Abstract][Full Text] [Related]
6. Effect of antidepressant treatment on peripheral inflammation markers - A meta-analysis.
Więdłocha M; Marcinowicz P; Krupa R; Janoska-Jaździk M; Janus M; Dębowska W; Mosiołek A; Waszkiewicz N; Szulc A
Prog Neuropsychopharmacol Biol Psychiatry; 2018 Jan; 80(Pt C):217-226. PubMed ID: 28445690
[TBL] [Abstract][Full Text] [Related]
7. [Efficacy of escitalopram vs paroxetine on severe depression with associated anxiety: data from the "Boulenger" study].
Chauvet-Gélinier JC
Encephale; 2010 Oct; 36(5):425-32. PubMed ID: 21035633
[TBL] [Abstract][Full Text] [Related]
8. Duloxetine versus escitalopram and placebo: an 8-month, double-blind trial in patients with major depressive disorder.
Pigott TA; Prakash A; Arnold LM; Aaronson ST; Mallinckrodt CH; Wohlreich MM
Curr Med Res Opin; 2007 Jun; 23(6):1303-18. PubMed ID: 17559729
[TBL] [Abstract][Full Text] [Related]
9. Escitalopram versus placebo in the treatment of dysthymic disorder.
Hellerstein DJ; Batchelder ST; Hyler S; Arnaout B; Toba C; Benga I; Gangure D
Int Clin Psychopharmacol; 2010 May; 25(3):143-8. PubMed ID: 21811192
[TBL] [Abstract][Full Text] [Related]
10. ATP-binding cassette sub-family F member 1 (ABCF1) is identified as a putative therapeutic target of escitalopram in the inflammatory cytokine pathway.
Powell TR; Tansey KE; Breen G; Farmer AE; Craig IW; Uher R; McGuffin P; D'Souza UM; Schalkwyk LC
J Psychopharmacol; 2013 Jul; 27(7):609-15. PubMed ID: 23719290
[TBL] [Abstract][Full Text] [Related]
11. Short-term effects of escitalopram on regional brain function in first-episode drug-naive patients with major depressive disorder assessed by resting-state functional magnetic resonance imaging.
Wang L; Li K; Zhang Q; Zeng Y; Dai W; Su Y; Wang G; Tan Y; Jin Z; Yu X; Si T
Psychol Med; 2014 May; 44(7):1417-26. PubMed ID: 23942213
[TBL] [Abstract][Full Text] [Related]
12. Cytokines: abnormalities in major depression and implications for pharmacological treatment.
O'Brien SM; Scott LV; Dinan TG
Hum Psychopharmacol; 2004 Aug; 19(6):397-403. PubMed ID: 15303243
[TBL] [Abstract][Full Text] [Related]
13. Natural killer cell cytotoxity and course of illness in depressed mood.
Reynaert C; Janne P; Jacques D; Tordeurs D; Zdanowicz N
Psychiatr Danub; 2010 Nov; 22 Suppl 1():S132-4. PubMed ID: 21057421
[TBL] [Abstract][Full Text] [Related]
14. Th1, Th2, and Th3 cytokine alterations in major depression.
Myint AM; Leonard BE; Steinbusch HW; Kim YK
J Affect Disord; 2005 Oct; 88(2):167-73. PubMed ID: 16126278
[TBL] [Abstract][Full Text] [Related]
15. Plasma biomarkers in a placebo-controlled trial comparing tDCS and escitalopram efficacy in major depression.
Brunoni AR; Padberg F; Vieira ELM; Teixeira AL; Carvalho AF; Lotufo PA; Gattaz WF; Benseñor IM
Prog Neuropsychopharmacol Biol Psychiatry; 2018 Aug; 86():211-217. PubMed ID: 29894705
[TBL] [Abstract][Full Text] [Related]
16. Escitalopram reduces circulating pro-inflammatory cytokines and improves depressive behavior without affecting sleep in a rat model of post-cardiac infarct depression.
Bah TM; Benderdour M; Kaloustian S; Karam R; Rousseau G; Godbout R
Behav Brain Res; 2011 Nov; 225(1):243-51. PubMed ID: 21824496
[TBL] [Abstract][Full Text] [Related]
17. Changes in cytokine and chemokine expression distinguish dysthymic disorder from major depression and healthy controls.
Ho PS; Yen CH; Chen CY; Huang SY; Liang CS
Psychiatry Res; 2017 Feb; 248():20-27. PubMed ID: 27992767
[TBL] [Abstract][Full Text] [Related]
18. Citalopram and escitalopram in the treatment of major depressive disorder: a pooled analysis of 3 clinical trials.
Li H; Li T; Li G; Luo J
Ann Clin Psychiatry; 2014 Nov; 26(4):281-7. PubMed ID: 25401715
[TBL] [Abstract][Full Text] [Related]
19. A randomized, double-blind, 24-week study of escitalopram (10 mg/day) versus citalopram (20 mg/day) in primary care patients with major depressive disorder.
Colonna L; Andersen HF; Reines EH
Curr Med Res Opin; 2005 Oct; 21(10):1659-68. PubMed ID: 16238906
[TBL] [Abstract][Full Text] [Related]
20. Is the significant superiority of escitalopram compared with other antidepressants clinically relevant?
Montgomery SA; Möller HJ
Int Clin Psychopharmacol; 2009 May; 24(3):111-8. PubMed ID: 19357527
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
